Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers

Ossenkoppele, Rik LU ; Reimand, Juhan ; Smith, Ruben LU ; Leuzy, Antoine LU ; Strandberg, Olof LU ; Palmqvist, Sebastian LU orcid ; Stomrud, Erik LU orcid ; Zetterberg, Henrik LU ; Scheltens, Philip and Dage, Jeffrey L. , et al. (2021) In EMBO Molecular Medicine 13(8).
Abstract

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([18F]RO948 in BioFINDER-2, [18F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau... (More)

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([18F]RO948 in BioFINDER-2, [18F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEɛ4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ-pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, CSF, PET, plasma, tau
in
EMBO Molecular Medicine
volume
13
issue
8
article number
e14398
publisher
Wiley-Blackwell
external identifiers
  • pmid:34254442
  • scopus:85111722211
ISSN
1757-4676
DOI
10.15252/emmm.202114398
language
English
LU publication?
yes
id
57de1938-6974-44e8-be6c-89f3066b14fd
date added to LUP
2021-08-30 15:13:56
date last changed
2024-06-16 17:55:07
@article{57de1938-6974-44e8-be6c-89f3066b14fd,
  abstract     = {{<p>PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)-related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n = 400) and ADNI (n = 371). All had tau-PET ([<sup>18</sup>F]RO948 in BioFINDER-2, [<sup>18</sup>F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEɛ4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ-pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.</p>}},
  author       = {{Ossenkoppele, Rik and Reimand, Juhan and Smith, Ruben and Leuzy, Antoine and Strandberg, Olof and Palmqvist, Sebastian and Stomrud, Erik and Zetterberg, Henrik and Scheltens, Philip and Dage, Jeffrey L. and Bouwman, Femke and Blennow, Kaj and Mattsson-Carlgren, Niklas and Janelidze, Shorena and Hansson, Oskar}},
  issn         = {{1757-4676}},
  keywords     = {{Alzheimer's disease; CSF; PET; plasma; tau}},
  language     = {{eng}},
  month        = {{08}},
  number       = {{8}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{EMBO Molecular Medicine}},
  title        = {{Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers}},
  url          = {{http://dx.doi.org/10.15252/emmm.202114398}},
  doi          = {{10.15252/emmm.202114398}},
  volume       = {{13}},
  year         = {{2021}},
}